Vontobel Holding Ltd. Lowers Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Vontobel Holding Ltd. decreased its holdings in Gilead Sciences, Inc. by 10.4% during the second quarter, now owning 205,293 shares valued at approximately $22.76 million.
• Gilead Sciences reported a quarterly earnings of $2.01 per share, exceeding analysts' expectations, with revenue of $7.08 billion for the quarter, up 1.4% year-over-year.
• The company recently declared a quarterly dividend of $0.79 per share, translating to an annualized dividend yield of 2.7% and a payout ratio of 62.95%.

Vontobel Holding Ltd. trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 205,293 shares of the biopharmaceutical company's stock after selling 23,818 shares during the period. Vontobel Holding Ltd.'s holdings in Gilead Sciences were worth $22,761,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the business. Smallwood Wealth Investment Management LLC bought a new stake in shares of Gilead Sciences in the first quarter worth about $25,000. Activest Wealth Management increased its holdings in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences in the first quarter worth about $29,000. Colonial Trust Advisors increased its holdings in shares of Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital increased its holdings in shares of Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 241 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 1.3%

GILD opened at $116.74 on Friday. The stock has a market cap of $144.85 billion, a price-to-earnings ratio of 23.26, a P/E/G ratio of 0.80 and a beta of 0.34. The stock's 50 day moving average price is $114.57 and its 200-day moving average price is $110.19. Gilead Sciences, Inc. has a one year low of $84.17 and a one year high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences's dividend payout ratio is currently 62.95%.

Analyst Ratings Changes

GILD has been the topic of several research reports. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the stock from $108.00 to $127.00 in a report on Friday, August 8th. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 16th. Citigroup boosted their price objective on Gilead Sciences from $125.00 to $135.00 and gave the stock a "buy" rating in a research note on Wednesday. Rothschild & Co Redburn boosted their price objective on Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a research note on Friday, September 12th. Finally, Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus target price of $118.08.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the transaction, the chief financial officer owned 159,555 shares of the company's stock, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at approximately $978,880.80. This represents a 35.92% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 82,000 shares of company stock worth $9,402,130. Corporate insiders own 0.27% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.